(R)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 | 911200-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奥昔康唑
• 中文名称: (R)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯
• 中文别名: (R)-5-烯丙基-2-氧杂双环[3.3.]辛-8-烯
• 英文名称: (R)-5-allyl-2-oxabicyclo[3.3.0]oct-8-ene
• 英文别名: (3aR)-3a-allyl-2,3,4,5-tetrahydrocyclopenta[b]furan；(3aR)-3a-prop-2-enyl-2,3,4,5-tetrahydrocyclopenta[b]furan
• CAS: 911200-98-1
• 化学式: C₁₀H₁₄O
• 分子量: 150.221
• InChiKey: WBRYUDKSKFXYOD-JTQLQIEISA-N

物化性质

• 沸点：
  217.2±7.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)
• 闪点：
  74°C(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 生成 2-[[(3aR,6aR)-3a-prop-2-enyl-3,4,5,6-tetrahydro-2H-cyclopenta[b]furan-6a-yl]oxy]propanediamide
  参考文献：
  名称：

  Nemoto Hisao, Tetrahedron Lett, 35 (1994) N 42, S 7785-7788

  摘要：

  DOI：

文献信息

• Synthetic studies of incednine: synthesis of C1–C13 pentaenoic acid segment
  作者：Takashi Ohtani、Hiroshi Kanda、Kensuke Misawa、Yoshifumi Urakawa、Kazunobu Toshima

  DOI：10.1016/j.tetlet.2009.02.203

  日期：2009.5

  Stereoselective synthesis of the C1–C13 pentaenoic acid segment (4) of the novel antibiotic incednine (1) is described.

  描述了新型抗菌素incednine（1）的C1-C13戊烯酸片段（4）的立体选择性合成。
• IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20150051190A1

  公开（公告）日：2015-02-19

  The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R 1 , G, T, Y 1 , Y 2 , Y 3 , and Y 4 are as defined herein.

  本发明旨在提供一种化合物或其药理学上可接受的盐，通过其对ROS1激酶酶活性的抑制作用和NTRK激酶酶抑制作用，在肿瘤治疗中具有用途。本发明提供了一种具有通式(I)所代表的咪唑并[1,2-b]吡啶结构的化合物或其药理学上可接受的盐，以及包含该化合物的药物组合物。在该式中，R1、G、T、Y1、Y2、Y3和Y4如本处所定义。
• BIPHENYLACETAMIDE DERIVATIVE
  申请人：Iwama Seiji

  公开号：US20110224304A1

  公开（公告）日：2011-09-15

  The present invention provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, C 1-6 alkyl, C 1-6 alkoxy substituted with fluorine atom, and others; R 4 and R 5 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, C 1-6 alkyl, C 1-6 alkoxy substituted with fluorine atom, and others; R 6 and R 7 are independently selected from the group consisting of hydrogen atom, fluorine atom, methyl, ethyl, hydroxy group, and others; and R 8 and R 9 are independently selected from the group consisting of hydrogen atom, C 1-6 alkyl, and others, which is useful as an agent for treating or preventing various types of epilepsy including partial seizures and/or generalized seizures.

  本发明提供了化合物的化学式（I）或其盐，其中R1、R2和R3分别独立地选自氢原子、氟原子、氯原子、溴原子、C1-6烷基、用氟原子取代的C1-6烷氧基等；R4和R5分别独立地选自氢原子、氟原子、氯原子、C1-6烷基、用氟原子取代的C1-6烷氧基等；R6和R7分别独立地选自氢原子、氟原子、甲基、乙基、羟基等；R8和R9分别独立地选自氢原子、C1-6烷基等，该化合物可用作治疗或预防各种类型的癫痫，包括部分发作和/或全面发作。
• Synthesis of Optically Active δ-Dodecalactone via Chiral Resolution Using CPF
  作者：Hisao Nemoto、Weihui Zhong、Tomoyuki Kawamura、Masaki Kamiya、Yasushi Nakano、Kei Sakamoto

  DOI：10.1055/s-2007-985604

  日期：2007.9

  (R)-6-Heptyltetrahydropyran-2-one and its S-enantiomer were synthesized via chiral resolution of (±)-1-undecen-4-ol by (R)-3a-allyl-3,3a,4,5-tetrahydro-2H-cyclopenta[b]furan (CPF). The R-enantiomer has sophisticated strong, fruity flavor, while the ­flavor of the S-enantiomer is soft and sweet, similar to apricot.

  (通过(R)-3a-烯丙基-3,3a,4,5-四氢-2H-环戊并[b]呋喃（CPF）手性解析(±)-1-十一烯-4-醇，合成了(R)-6-庚基四氢吡喃-2-酮及其 S-对映体。R-enantiomer 具有浓郁的水果香味，而 S-enantiomer 的味道则柔和甜美，类似杏子的味道。
• GLYCINE TRANSPORTER INHIBITOR
  申请人：TAISHO PHARMACEUTICAL CO., LTD.

  公开号：US20160159814A1

  公开（公告）日：2016-06-09

  The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

  本发明提供了式[I]或其药学上可接受的盐的新化合物，其可用于预防或治疗诸如精神分裂症、阿尔茨海默病、认知障碍、痴呆、焦虑症（例如广泛性焦虑症、惊恐症、强迫症、社交性焦虑症、创伤后应激障碍、特定恐惧症、急性应激障碍）、抑郁症、药物依赖、痉挛、震颤、疼痛、帕金森病、注意力缺陷多动障碍、双相情感障碍、进食障碍或睡眠障碍等疾病，其基于甘氨酸摄取抑制作用。